Efficacy, Safety, and Survival Findings after Long-Term Follow-up from ZGJAK002, a Phase 2 Study Comparing Jaktinib 100 Mg Twice Daily with 200 Mg Once Daily for Myelofibrosis (MF)
Year: 2023
Type: conference-abstract
Source: Blood
Institutions: First Affiliated Hospital Zhejiang University, Zhengzhou University, Henan Cancer Hospital, First Affiliated Hospital of Zhengzhou University, Central South University, Xiangya Hospital Central South University, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital, First Hospital of Jilin University, Peking University People's Hospital, Jilin University, Second Affiliated Hospital of Jilin University, Sir Run Run Shaw Hospital, Zhejiang University, Sichuan University, West China Hospital of Sichuan University, Shanxi Medical University, Second Hospital of Shanxi Medical University, Twelfth Guangzhou City People's Hospital, Guangdong Provincial People's Hospital, First Affiliated Hospital of Nanchang University, First Affiliated Hospital of Anhui Medical University, First Affiliated Hospital of Bengbu Medical College, Fujian Medical University, Union Hospital, First Hospital of China Medical University, Wuhan Union Hospital, Huazhong University of Science and Technology, Second Xiangya Hospital of Central South University, Jiangxi Provincial People's Hospital, Henan Provincial People's Hospital, Kunming Medical University, Second Affiliated Hospital of Kunming Medical College
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4389258339